Company

VarmX B.V.

Leiden biopharmaceutical company developing VMX-C001, an agent that restores blood coagulation in FXa-DOAC patients.

About

VarmX B.V. develops VMX-C001, a universal bypassing agent for managing bleeding in patients taking Factor Xa direct oral anticoagulants. Founded in 2016 in Leiden, Netherlands, by Pieter Reitsma, the company is led by CEO Jeffrey Lawson. It has completed 7 deals and raised a total of EUR 32.00 mn, with its latest Series B led by Sound Bioventures.

4Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in